TGFBR2 and neoplasm: Other studies have shown that the inhibition of the endogenous TGF-β receptor (TGFBR2) signal in CAR-T cells enhanced the anti-tumor function of ROR1-specific CAR-T cells against triple-negative breast cancer by reducing Treg conversion and also prevented the exhaustion of CAR-T cells (26, 27).